Biovaxys Technology Corp. (BVAXF)
OTC PINK OTC PINK Primary 
Sona Nanotech teams with BioVaxys on cancer tech – ICYMI
Sona Nanotech Inc earlier this week announced a research collaboration with BioVaxys to explore potential synergy between their respective cancer therapy technologies. The company said the agreement will focus on combining its targeted hyperthermia therapy (THT) with BioVaxys's DPX technology.
Sona Nanotech and BioVaxys partner to develop novel cancer therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is joining forces with BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) to explore a new approach to cancer treatment. The two companies are collaborating on research that brings together Sona's Targeted Hyperthermia Therapy (THT) and BioVaxys' DPX Immune Educating Platform, with the goal of developing a next-generation cancer therapy.
BioVaxys and Sona Nanotech Enter Research Collaboration
VANCOUVER, BC and HALIFAX, NS , May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPXâ„¢ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapyâ„¢ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod ("GNR") technology which elicits a strong immune response.
BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. VANCOUVER, BC , Jan. 14, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage company developing a portfolio of vaccines based on its novel DPXâ„¢ immune educating platform to treat a range of cancers, infectious diseases, and immune modulated disorders, is pleased to announce that it has been invited to present on the Emerging Growth Conference at 3:25PM - 3:35PM Eastern Time on Thursday January 16, 2025.
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up
VANCOUVER, BC , Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, it has acquired a 48-kilogram ("kg") supply of GMP-grade lipid to enable production of the Company's DPX antigen packaging delivery platform. These unused lipids from the former IMV, Inc., had been previously produced in advance of anticipated IMV clinical studies and commercial ramp up.
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium
VANCOUVER, BC , Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats. The RRPV is a multiple-purpose acquisition vehicle to facilitate end-to-end development of future medical countermeasures, from the early stage through the advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development.
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market 1 VANCOUVER, BC , Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPXâ„¢, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems. With cancer vaccines, the successful eradication of tumors relies on the persistent delivery of antigenic APCs to prime potent, antigen specific, cytotoxic T cells.
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024
BioVaxys invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation on the Emerging Growth Conference. VANCOUVER, BC , Oct. 28, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPXâ„¢ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Emerging Growth Conference on October 30 th, 2024 at 9:40 AM EST.
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor
VANCOUVER, BC , Oct. 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPXâ„¢ formulations. Dr. Rajagopalan has a PhD in Pharmaceutical Chemistry/Physical Chemistry, with over 20 years of experience in nanoparticles formulation development for biomolecules (peptides, proteins, nucleic acids, VLPs, mAbs) delivery to treat cancer, infectious diseases and autoimmune disorders.
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com
BioVaxys to Present at the Life Sciences Investor Forum on September 19th
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com VANCOUVER, BC , Sept. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPXâ„¢ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19 th, 2024.
BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit
VANCOUVER, BC , Sept. 4, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") is pleased to announce that it has been invited to present "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies" at The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) to be held December 3-5, 2024, in Boston, MA.
